These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15761719)

  • 1. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
    Nauck MA; El-Ouaghlidi A
    Diabetologia; 2005 Apr; 48(4):608-11. PubMed ID: 15761719
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
    Holst JJ; Deacon CF
    Diabetologia; 2005 Apr; 48(4):612-5. PubMed ID: 15759106
    [No Abstract]   [Full Text] [Related]  

  • 3. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
    Ahrén B
    Diabetologia; 2005 Apr; 48(4):605-7. PubMed ID: 15770467
    [No Abstract]   [Full Text] [Related]  

  • 6. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
    Holst JJ; Deacon CF
    Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
    Holst JJ
    Adv Exp Med Biol; 2003; 524():263-79. PubMed ID: 12675249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric bypass and nesidioblastosis--too much of a good thing for islets?
    Cummings DE
    N Engl J Med; 2005 Jul; 353(3):300-2. PubMed ID: 16034017
    [No Abstract]   [Full Text] [Related]  

  • 11. Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
    Demuth HU; Hinke SA; Pederson RA; McIntosh CH
    Biochem Biophys Res Commun; 2002 Aug; 296(2):229-32. PubMed ID: 12163006
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastro-intestinal hormones GIP and GLP-1.
    Kieffer TJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):13-21. PubMed ID: 15122087
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.
    Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Dunning BE; Foley JE; Rizza RA; Camilleri M
    Diabetes; 2007 May; 56(5):1475-80. PubMed ID: 17303799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
    Fehmann HC; Göke B
    Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
    [No Abstract]   [Full Text] [Related]  

  • 16. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut hormones and related concepts.
    Bloomgarden ZT
    Diabetes Care; 2006 Oct; 29(10):2319-24. PubMed ID: 17003315
    [No Abstract]   [Full Text] [Related]  

  • 18. GLP-1 and the gut.
    Thompson DG
    Gut; 2000 May; 46(5):591. PubMed ID: 10764696
    [No Abstract]   [Full Text] [Related]  

  • 19. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.